Corrected: China's BioDlink International HY revenue falls (September 29)

BioDlink International

29/09/2026 10:29

Corrects first overview bullet in Sept. 29 story to change revenue unit to million from billion

Overview
China CDMO provider's half-year revenue fell to RMB 246 mln
Company expanded CDMO operations and invested in R&D during the reporting period
WuXi XDC completed acquisition, bringing new leadership and strategic direction

Outlook
Company did not provide specific financial guidance in the interim report

Result Drivers
CDMO EXPANSION - Co said accelerated expansion of CDMO operations contributed to results
PRODUCT PRESSURE – Product revenue fell 89% yr/yr to RMB45 mln, mainly due to intensified market competition and volume-based procurement
R&D RESOURCE REALLOCATION – R&D expenses fell 25% yr/yr to RMB27 mln as product pipelines were streamlined and resources shifted to CDMO development

Company press release: Full Story

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 246.01 mln
 

Analyst Coverage
The one available analyst rating on the shares is "strong buy"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for BioDlink International Co Ltd is HK$4.40, about 17.3% above its September 28 closing price of HK$3.75

Reuters Recommended Reads
Sept 28 - China's Fudan Microelectronics HY revenue, profit rise
Sept 29 - Novo Nordisk to license GLP-1 drug from China's Hengrui in $2.6 billion deal
Sept 28 - France's Inventiva H1 net loss narrows

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Press Release https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0929/2026092901031.pdf
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)